Nexataf
Generic Name
Tenofovir Alafenamide
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| nexataf 25 mg tablet | ৳ 90.00 | N/A |
Description
Overview of the medicine
Nexataf 25 mg Tablet contains Tenofovir Alafenamide (TAF), an antiretroviral medication used to treat chronic hepatitis B virus (HBV) infection in adults and adolescents, and as part of combination therapy for human immunodeficiency virus type 1 (HIV-1) infection. It works by inhibiting viral replication.
Uses & Indications
Dosage
Adults
For HBV: 25 mg once daily. For HIV: 25 mg once daily, in combination with other antiretroviral agents.
Elderly
No dose adjustment generally required, but caution due to potential decreased renal function.
Renal_impairment
For eGFR ≥15 mL/min: No dose adjustment. For eGFR <15 mL/min or hemodialysis: Not recommended unless potential benefits outweigh risks, or follow specific guidelines for use with caution.
How to Take
Oral administration. Take with food. Do not chew, crush, or split the tablet.
Mechanism of Action
Tenofovir Alafenamide is a phosphonamidate prodrug of tenofovir. After oral administration, it is rapidly absorbed and metabolized intracellularly to tenofovir diphosphate, the active antiviral metabolite. Tenofovir diphosphate inhibits HBV reverse transcriptase and HIV-1 reverse transcriptase by competing with deoxyadenosine 5'-triphosphate, leading to DNA chain termination and inhibition of viral replication.
Pharmacokinetics
Onset
Antiviral effect within days to weeks.
Excretion
Primarily renal excretion of tenofovir (active metabolite) after intracellular conversion.
Half life
TAF: 0.2-0.5 hours; Tenofovir (intracellular): approximately 32 hours (diphosphate).
Absorption
Rapidly absorbed after oral administration, peak plasma concentrations of TAF reached within 0.5-2 hours.
Metabolism
Primarily metabolized intracellularly by cathepsin A in peripheral blood mononuclear cells (PBMCs) and hepatocytes to tenofovir.
Side Effects
Contraindications
- Known hypersensitivity to tenofovir alafenamide or any components of the tablet.
- Not indicated for HIV-1 pre-exposure prophylaxis (PrEP).
Drug Interactions
Strong P-gp inhibitors (e.g., cyclosporine)
May increase TAF plasma concentrations.
Dofetilide, amiodarone, dabigatran, digoxin, quinidine
Use with caution due to potential for increased concentrations of these drugs.
Strong P-gp inducers (e.g., rifampin, St. John's Wort)
May significantly decrease TAF plasma concentrations, leading to loss of therapeutic effect. Co-administration is not recommended.
Certain anticonvulsants (e.g., carbamazepine, oxcarbazepine, phenobarbital, phenytoin)
May decrease TAF concentrations.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
There is no specific antidote for overdose with tenofovir alafenamide. If overdose occurs, the patient should be monitored for evidence of toxicity, and standard supportive treatment should be applied as necessary. Hemodialysis can remove tenofovir.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have shown no evidence of impaired fertility or harm to the fetus. Use during pregnancy only if clearly needed and potential benefits outweigh risks. It is not known whether TAF is excreted in human milk. Due to potential for adverse effects on breastfed infants, mothers receiving TAF should be instructed not to breastfeed.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Patented by Gilead Sciences
WHO Essential Medicine
YesClinical Trials
Extensive clinical trials have demonstrated the efficacy and safety of tenofovir alafenamide in both HIV and HBV infected patients, showing improved renal and bone safety profiles compared to tenofovir disoproxil fumarate (TDF).
Lab Monitoring
- Renal function (eGFR, serum creatinine, urine protein) prior to and during treatment.
- Hepatic function (ALT, AST) prior to and during treatment.
- Serum phosphate (for patients at risk of renal dysfunction).
- Bone mineral density (for patients with history of fracture or at risk of bone loss).
Doctor Notes
- Monitor renal function and bone mineral density periodically, especially in patients with pre-existing conditions or risk factors.
- Educate patients on the importance of adherence and not discontinuing treatment without medical advice, particularly for HBV.
- Be aware of potential drug interactions with P-gp inducers/inhibitors.
Patient Guidelines
- Take the tablet orally once daily with food.
- Do not stop taking the medicine without consulting your doctor, especially if you have Hepatitis B.
- Report any new or worsening symptoms to your doctor immediately.
- Adhere strictly to the prescribed dosage and regimen.
Missed Dose Advice
If a dose is missed within 18 hours of the scheduled time, take it as soon as possible with food. If more than 18 hours have passed, skip the missed dose and take the next dose at the regularly scheduled time. Do not take a double dose.
Driving Precautions
May cause dizziness or fatigue. Patients should be advised to exercise caution when driving or operating machinery until they know how Nexataf affects them.
Lifestyle Advice
- Maintain a healthy diet and stay hydrated.
- Avoid alcohol consumption, especially if you have liver issues.
- Practice safe sex to prevent transmission of HIV/HBV.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.